(RTTNews) - Lipocine (LPCN) announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 or oral brexanolone for the treatment of postpartum depression. In the trial, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D t
9 views
Lipocine: LPCN 1154 Fails To Meet Primary Endpoint; Plans To Evaluate All Available Options
(RTTNews) - Lipocine (LPCN) announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 or oral brexanolone for the treatment of postpartum depression. In the trial, LPCN 1154 did not show…
